论文部分内容阅读
目的:研究非小细胞肺癌中nm23 mRNA表达水平与肺癌临床病理特征及预后之间的关系。方法:53例肺癌标本,44例(癌旁)正常肺组织,用RT-PCR方法检测标本中nm23 mRNA的表达水平,根据手术、病理和影像学结果判断有无转移并确定分期,就nm23 mRNA表达水平与临床变量之间进行分析。结果:nm23 mRNA在肺癌和(癌旁)正常肺组织中的表达阳性率分别为43．4％(23／53)和40．9％(18／44),P>0．05;在低分化、晚期、肺门纵隔淋巴结转移的非小细胞肺癌中,其nm23 mRNA的表达量显著降低(P<0．05),nm23 mRNA表达阳性和阴性的患者中位生存期分别为43个月和46个月,其表达量与患者的预后之间未发现显著相关性(P>0．05)。结论:nm23 mRNA的表达与肺癌的分化、转移及病理分期有关,但尚无足够证据显示其与肺癌的预后有相关关系。
Objective: To study the relationship between the expression of nm23 mRNA in non-small cell lung cancer (NSCLC) and clinicopathological features and prognosis of lung cancer. Methods: The expression of nm23 mRNA was detected by RT-PCR in 53 cases of lung cancer and 44 cases of normal lung tissue. The metastasis of the tumor was evaluated by the results of surgery, pathology and radiology. The expression of nm23 mRNA The level of expression was analyzed between clinical variables. Results: The positive rates of nm23 mRNA expression in lung cancer and normal lung tissues were 43.4% (23/53) and 40.9% (18/44) respectively, P> 0.05. In poorly differentiated , The expression of nm23 mRNA was significantly lower in patients with advanced hilar mediastinal lymph node metastasis (P <0.05). The median survival time of patients with positive and negative nm23 mRNA expression was 43 months and 46 For months, no significant correlation was found between the expression level and the prognosis of patients (P> 0.05). Conclusion: The expression of nm23 mRNA is related to the differentiation, metastasis and pathological stage of lung cancer. However, there is not enough evidence to show that it correlates with the prognosis of lung cancer.